The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Open accessAbstract
BACKGROUND: Inclisiran inhibits hepatic synthesis of proprotein convertase subtilisin-kexin type 9. Previous studies suggest that inclisiran might provide sustained reductions in low-density lipoprotein (LDL) cholesterol levels with infrequent dosing. METHODS: We enrolled patients with atherosclerotic cardiovascular disease (ORION-10 trial) and patients with atherosclerotic cardiovascular disease or an atherosclerotic cardiovascular disease risk equivalent (ORION-11 trial) who had elevated LDL cholesterol levels despite receiving statin therapy at the maximum tolerated dose. Patients were randomly assigned in a 1:1 ratio to receive either inclisiran (284 mg) or placebo, administered by subcutaneous injection on day 1, day 90, and every 6 months thereafter over a period of 540 days. The coprimary end points in each trial were the placebo-corrected percentage change in LDL cholesterol level from baseline to day 510 and the time-adjusted percentage change in LDL cholesterol level from baseline after day 90 and up to day 540. RESULTS: A total of 1561 and 1617 patients underwent randomization in the ORION-10 and ORION-11 trials, respectively. Mean (±SD) LDL cholesterol levels at baseline were 104.7±38.3 mg per deciliter (2.71±0.99 mmol per liter) and 105.5±39.1 mg per deciliter (2.73±1.01 mmol per liter), respectively. At day 510, inclisiran reduced LDL cholesterol levels by 52.3% (95% confidence interval [CI], 48.8 to 55.7) in the ORION-10 trial and by 49.9% (95% CI, 46.6 to 53.1) in the ORION-11 trial, with corresponding time-adjusted reductions of 53.8% (95% CI, 51.3 to 56.2) and 49.2% (95% CI, 46.8 to 51.6) (P<0.001 for all comparisons vs. placebo). Adverse events were generally similar in the inclisiran and placebo groups in each trial, although injection-site adverse events were more frequent with inclisiran than with placebo (2.6% vs. 0.9% in the ORION-10 trial and 4.7% vs. 0.5% in the ORION-11 trial); such reactions were generally mild, and none were severe or persistent. CONCLUSIONS: Reductions in LDL cholesterol levels of approximately 50% were obtained with inclisiran, administered subcutaneously every 6 months. More injection-site adverse events occurred with inclisiran than with placebo. (Funded by the Medicines Company; ORION-10 and ORION-11 ClinicalTrials.gov numbers, NCT03399370 and NCT03400800.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Randomized controlled trials, including the VICTORION-Mono and VICTORION-Difference trials, as well as ORION -10, -11, and other Phase III trials, have consistently demonstrated that inclisiran reduces LDL-C compared with placebo in primary and secondary prevention settings.5, 6, 7”
From Small Interfering RNA for LDL-Cholesterol Reduction (2026) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The trials showed that patients achieved LDL-C decreases of 52.3% and 49.9% at Day 510 [44].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The ORION-10 and ORION-11 trials achieved LDL-C reductions greater than 50% among their participants [44].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The initial injections of inclisiran at Day 1 and 90 followed by biannual maintenance resulted in a long-term average LDL-C reduction of − 44% to − 48% across ORION-1 and ORION-10 and ORION-11 [25, 44].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical observations demonstrate that numerous patients stop taking their daily statin medications or PCSK9 antibody injections irregularly which reduces their ability to prevent cardiovascular diseases [44, 80].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [44]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Accordingly, PCSK9 siRNA and monoclonal antibodies blocking the PCSK9/LDLR interaction potently lower LDL cholesterol and reduce the risk of adverse cardiovascular events (Sabatine et al., 2017; Schwartz et al., 2018; Ray et al., 2020).”
From PCSK9 deficiency alters brain lipid composition without affecting brain development and function (2023) · cites this paper as Ray et al., 2020
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Accordingly, PCSK9 inhibitory antibodies and siRNA potently reduce LDL cholesterol to unprecedented low levels and are approved for treatment of hypercholesterolemia.”
From PCSK9 deficiency alters brain lipid composition without affecting brain development and function (2023) · cites this paper as Ray et al., 2020
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“targeted PCSK9 inhibition restores hepatic LDLR levels, decreases plasma LDL-C levels and improves cardiovascular outcomes.7,9–11”
From Sirtuin-1 directly binds and deacetylates hepatic PCSK9 thereby promoting the inhibition of LDL receptor degradation (2025) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The phase 3 ORION-10 and ORION-11 trials evaluated inclisiran compared with placebo across a total of 1561 and 1617 patients with atherosclerosis or an atherosclerotic CVD risk-equivalent, respectively [137]. Compared with placebo, inclisiran reduced LDL-C levels by − 52% and − 50%, respectively.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [137]
The cited source says what the claim attributes to it.
In the citing paper
“In addition to monoclonal antibodies that sequester PCSK9 in the circulation and are now prescribed to patients, the small-interfering RNA inclisiran that targets PCSK9 hepatic production has recently been approved, following reports of substantial LDL lowering [50% reduction (95% confidence interval 47–53)] with this drug (11).”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“In addition to the monoclonal antibodies, an siRNA, inclisiran, which also targets PSCK9, has demonstrated the ability to reduce LDL cholesterol by 49-52% in trials evaluating individuals with established cardiovascular disease or ASCVD risk equivalent (129).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [129]
The cited source says what the claim attributes to it.
In the citing paper
“In addition to the monoclonal antibodies, an siRNA, inclisiran, which also targets PSCK9 and is referred to as a PCSK9 siRNA in this section, has demonstrated the ability to reduce LDL cholesterol by 49–52% in trials evaluating individuals with established CVD or ASCVD risk equivalent (123).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [123]
The cited source says what the claim attributes to it.
In the citing paper
“Inclisiran was noted to decrease LDL by ∼50% in the ORION trials [20]”
From Oral PCSK9 inhibitors for elevated LDL-C: A systematic review and meta-analysis of randomized trials (2026) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“The analysis of 11 RCTs for quantitative synthesis included more than 13,000 participants showed inclisiran produces significant LDL-C reduction versus placebo treatment [24, 25, 38–44, 46, 49].”
The cited source says what the claim attributes to it.
In the citing paper
“Large-scale research including well-powered trials such as ORION 10 and ORION 11 demonstrates that Inclisiran shows strong potential as a potent lipid-lowering agent [44].”
In the citing paper
“Patients on statins with high LDL-C levels and ASCVD or at least one ASCVD risk equivalent were included in the two phase 3 trials ORION-10 and ORION-11 (Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol), and obtained a further 50% reduction of LDL-C with inclisiran.278”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [278]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Self-citationEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.003 · Cited by 2,691
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Ray, K. K., Landmesser, U., Leiter, L. A., Kallend, D., Dufour, R., Karakas, M., Hall, T., Troquay, R. P. T., Turner, T., Visseren, F. L. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615758 · Cited by 992
Self-citationRodríguez, F., Maron, D. J., Knowles, J. W., Virani, S. S., Lin, S., & Heidenreich, P. A. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2018.4936 · Cited by 347
The Implications of Therapeutic Complexity on Adherence to Cardiovascular Medications
Choudhry, N. K., Fischer, M. A., Avorn, J., Liberman, J. N., Schneeweiß, S., Pakes, J., Brennan, T. A., & Shrank, W. H. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.495 · Cited by 314
Cited by
Sorted by citations
Items 301–400 of 1,007
PCSK9, A Promising Novel Target for Age-Related Cardiovascular Dysfunction
Mátyás, C., Trojnár, E., Zhao, S., Arif, M., Mukhopadhyay, P., Kovács, A. D., Fábián, A., Tokodi, M., Bagyura, Z., Merkely, B. P., et al. (2023) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2023.06.005 · Cited by 34
MK-0616: an oral PCSK9 inhibitor for hypercholesterolemia treatment
Burnett, J. R., & Hooper, A. J. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2267972 · Cited by 36
Therapeutic Potential of Lipoprotein(a) Inhibitors
Nicholls, S. J. (2024) · Drugs · doi:10.1007/s40265-024-02046-z · Cited by 39
Qin, T., Ma, T., Huang, K., Lu, S., Zhong, J., & Li, J. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01215-5 · Cited by 36
Ray, A., Alabarse, P. V. G., Malik, R., Sargurupremraj, M., Bernhagen, J., Dichgans, M., Baumeister, S., & Georgakis, M. K. (2025) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2025.06.001 · Cited by 39
New Horizons in Pharmacologic Therapy for Secondary Stroke Prevention
Katsanos, A. H., & Hart, R. G. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.2494 · Cited by 34
Low‐density lipoprotein cholesterol and lifespan: A Mendelian randomization study
Daghlas, I., & Gill, D. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14811 · Cited by 34
PCSK9-targeted therapies: present and future approaches
Rifai, M. A., & Ballantyne, C. M. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00634-0 · Cited by 36
Residual risks and evolving atherosclerotic plaques
Noothi, S. K., Ahmed, M. R., & Agrawal, D. K. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04689-0 · Cited by 37
Targeted Degradation of PCSK9 In Vivo by Autophagy-Tethering Compounds
Ouyang, Z., Ma, M., Zhang, Z., Wu, H., Xue, Y., Jian, Y., Yin, K., Yu, S., Zhao, C., Guo, W., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01634 · Cited by 36
Brandts, J., & Ray, K. K. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1778668 · Cited by 33
Self-citationNovel Lipid-Lowering Therapies to Reduce Cardiovascular Risk
Wilkins, J. T., & Lloyd‐Jones, D. M. (2021) · JAMA · doi:10.1001/jama.2021.2244 · Cited by 33
Fàbrega, C., Aviñó, A. M., Navarro, N., Jorge, A. F., Grijalvo, S., & Eritja, R. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020320 · Cited by 34
Srivastava, R. A. K. (2023) · Cells · doi:10.3390/cells12121648 · Cited by 40
Gene editing for dyslipidemias: New tools to “cut” lipids
Stankov, S. G., & Cuchel, M. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.01.010 · Cited by 34
Interactions between PCSK9 and NLRP3 inflammasome signaling in atherosclerosis
Wang, Y., Fang, D., Yang, Q., You, J., Wang, L., Wu, J., Zeng, M., & Luo, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1126823 · Cited by 36
Long-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature
Schonck, W. A. M., Stroes, E. S. G., Hovingh, G. K., & Reeskamp, L. F. (2024) · Drugs · doi:10.1007/s40265-024-01995-9 · Cited by 34
Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand?
Tsioulos, G., Kounatidis, D. C., Vallianou, N. G., Poulaki, A., Kotsi, E., Christodoulatos, G. S., Tsilingiris, D., Karampela, Ι., Skourtis, A., & Dalamaga, Μ. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063537 · Cited by 36
Lipoprotein(a) Lowering—From Lipoprotein Apheresis to Antisense Oligonucleotide Approach
Greco, M. F., Sirtori, C. R., Corsini, A., Владиславович, Е. М., Sampietro, T., & Ruscica, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072103 · Cited by 33
RNA Silencing in the Management of Dyslipidemias
Henney, N. C., Banach, M., & Penson, P. E. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00968-7 · Cited by 32
PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance
Jia, X., Rifai, M. A., Saeed, A., Ballantyne, C. M., & Virani, S. S. (2022) · Vascular Health and Risk Management · doi:10.2147/vhrm.s275739 · Cited by 34
A promising therapy for fatty liver disease: PCSK9 inhibitors
Han, L., Wu, L., Yin, Q., Li, L., Zheng, X., Du, S., Huang, X., Bai, L., Wang, Y., & Bian, Y. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155505 · Cited by 31
Alradwan, I. A., Fayez, N. A., Alomary, M. N., Alshehri, A. A., Aodah, A. H., Almughem, F. A., Alsulami, K. A., Aldossary, A. M., Alawad, A. O., Tawfik, Y. M. K., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16081037 · Cited by 38
Inclisiran, Reasons for a Novel Agent in a Crowded Therapeutic Field
Barbagallo, F. D. G., Andreychuk, N., Scicali, R., González-Lleó, A. M., Piro, S., Masana, L., & Ibarretxe, D. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01271-x · Cited by 34
RNA Therapeutics: Delivery Problems and Solutions—A Review
Pozdniakova, N. V., Generalov, E. A., Shevelev, A. B., & Tarasova, O. A. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17101305 · Cited by 37
Lee, J. S., O’Connell, E. M., Pacher, P., & Lohoff, F. W. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081758 · Cited by 31
RNAi-based modulation of IFN-γ signaling in skin
Tang, Q., Sousa, J., Echeverria, D., Fan, X., Hsueh, Y.-C., Afshari, K., MeHugh, N., Cooper, D., Vangjeli, L., Monopoli, K. R., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.04.019 · Cited by 30
Evolving Diagnostic and Management Advances in Coronary Heart Disease
Ribeiro, M. D. O. L., Correia, V. M., de Oliveira, L. L. H., Soares, P. R., & Scudeler, T. L. (2023) · Life · doi:10.3390/life13040951 · Cited by 32
New Approaches for Targeting PCSK9: Small-Interfering Ribonucleic Acid and Genome Editing
Oostveen, R. F., Khera, A. V., Kathiresan, S., Stroes, E. S. G., Fitzgerald, K., Harms, M. J., Oakes, B. L., & Kastelein, J. J. P. (2023) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.122.317963 · Cited by 31
Self-citationEfficacy and Safety of Inclisiran in Asian Patients
Huo, Y., Lesogor, A., Lee, C. W., Chiang, C.-E., Mena-Madrazo, J., Poh, K. K., Jeong, M. H., Maheux, P., Zhang, M., Wei, S., et al. (2024) · JACC: Asia · doi:10.1016/j.jacasi.2023.09.006 · Cited by 31
Small circular interfering RNAs (sciRNAs) as a potent therapeutic platform for gene-silencing
Jahns, H., Degaonkar, R., Podbevšek, P., Gupta, S., Bisbe, A., Aluri, K. C., Szeto, J., Kumar, P., LeBlanc, S., Racie, T., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab724 · Cited by 33
Targeting a cell-specific microRNA repressor of CXCR4 ameliorates atherosclerosis in mice
Çimen, İ., Natarelli, L., Kichi, Z. A., Henderson, J. M., Farina, F. M., Briem, E., Aslani, M., Megens, R. T. A., Jansen, Y. J. F. M., Mann-Fallenbuchel, E., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adf3357 · Cited by 31
Advances in nucleic acid-targeted therapies for cardiovascular disease prevention
Makhmudova, U., Steinhagen‐Thiessen, E., Volpe, M., & Landmesser, U. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae136 · Cited by 31
Jiao, J., Qian, Y., Lv, Y., Wei, W., Long, Y., Guo, X., Buerliesi, A., Ye, J., Han, H., Li, J., et al. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107469 · Cited by 33
Recaticimab as Add-On Therapy to Statins for Nonfamilial Hypercholesterolemia
Sun, Y., Lv, Q., Guo, Y., Wang, Z., Huang, R., Gao, X., Han, Y., Yao, Z., Zheng, M., Luo, S., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.09.012 · Cited by 32
Epigenetic modifications and emerging therapeutic targets in cardiovascular aging and diseases
Qiu, Y., Xu, Q., Xie, P., He, C., Li, Q., Yao, X., Mao, Y. H., Wu, X., & Zhang, T. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107546 · Cited by 33
Galli, M., Abbate, A., Bonaca, M. P., Crea, F., Forte, M., Frati, G., Gaudino, M. F. L., Gibson, C. M., Gorog, D. A., Mehran, R., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01249-z · Cited by 41
Overcoming Barriers: Clinical Translation of siRNA Nanomedicines
Tieu, T., Wei, Y., Cifuentes‐Rius, A., & Voelcker, N. H. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100108 · Cited by 31
Jones, J. E., Tang, K. S., Barseghian, A., & Wong, N. D. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12237432 · Cited by 34
Muro, F. M. D., Vogel, B., Sartori, S., Bay, B., Oliva, A., Feng, Y., Krishnan, P., Sweeny, J. M., Gitto, M., Smith, K. F., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf112 · Cited by 31
Estimation of the major cardiovascular events prevention with Inclisiran
Cordero, A., Santos‐Gallego, C. G., Fácila, L., Rodríguez‐Mañero, M., Bertomeu‐González, V., Castellano, J. M., Seijas‐Amigo, J., Núñez, J. E., Zuazola, P., González‐Juanatey, J. R., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.09.021 · Cited by 29
New and emerging lipid-modifying drugs to lower LDL cholesterol
Kosmas, C. E., Pantou, D., Sourlas, A., Papakonstantinou, E. J., Uceta, R. E., & Guzman, E. (2021) · Drugs in Context · doi:10.7573/dic.2021-8-3 · Cited by 32
The promising novel therapies for familial hypercholesterolemia
Chen, R., Lin, S., & Chen, X. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24552 · Cited by 30
Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol
Samuel, E., Watford, M., Egolum, U. O., Ombengi, D., Ling, H., & Cates, D. W. (2022) · Annals of Pharmacotherapy · doi:10.1177/10600280221105169 · Cited by 30
Safety of Statins and Nonstatins for Treatment of Dyslipidemia
Newman, C. B. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.01.004 · Cited by 32
Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers
Chong, E. W., Joncas, F., Seidah, N. G., Calon, F., Diorio, C., & Gangloff, A. (2022) · BMC Cancer · doi:10.1186/s12885-022-10120-6 · Cited by 30
Management of Peripheral Arterial Disease: Lifestyle Modifications and Medical Therapies
King, R. W., Canonico, M. E., Bonaca, M. P., & Hess, C. N. (2022) · Journal of the Society for Cardiovascular Angiography & Interventions · doi:10.1016/j.jscai.2022.100513 · Cited by 35
Luo, M., Liu, Y., Xu, X., Liu, K., Shen, C., Hu, H., He, Z., & Wu, F. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1158274 · Cited by 29
Morton, J. I., Marquina, C., Lloyd, M., Watts, G. F., Zoungas, S., Liew, D., & Ademi, Z. (2023) · PharmacoEconomics · doi:10.1007/s40273-023-01306-2 · Cited by 29
Dron, J. S., Patel, A. P., Zhang, Y., Jurgens, S. J., Maamari, D. J., Wang, M., Boerwinkle, E., Morrison, A. C., de Vries, P. S., Fornage, M., et al. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2022.5271 · Cited by 30
New Insights Into the Treatment of Hyperlipidemia: Pharmacological Updates and Emerging Treatments
Abbasi, S., Khan, A. A., & Choudhry, M. W. (2024) · Cureus · doi:10.7759/cureus.63078 · Cited by 35
Linthout, S. V., Stellos, K., Giacca, M., Bertero, E., Cannata, A. N., Carrier, L., García‐Pavía, P., Ghigo, A., González, A., Haugaa, K. H., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3516 · Cited by 29
Real-World Efficacy and Safety of Inclisiran
Gargiulo, P., Marzano, F., Crisci, M., Marcucci, R., Bruzzese, D., Maloberti, A., Sarullo, F. M., Galasso, G., Indolfi, C., Musumeci, G., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.10.106 · Cited by 29
Nanoparticles Used for the Delivery of RNAi-Based Therapeutics
Ren, T., Ma, L., Fu, P., & Zhang, C. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17111502 · Cited by 31
Safety of proprotein convertase subtilisin/kexin 9 inhibitors: a systematic review and meta-analysis
Li, J., Du, H., Wang, Y., Aertgeerts, B., Guyatt, G. H., Hao, Q., Shen, Y., Li, L., Su, N., Delvaux, N., et al. (2022) · Heart · doi:10.1136/heartjnl-2021-320556 · Cited by 29
Effects of Lipid-Modifying and Other Drugs on Lipoprotein(a) Levels—Potent Clinical Implications
Koutsogianni, A. D., Liamis, G. L., Liberopoulos, E. N., Adamidis, P. S., & Florentin, M. (2023) · Pharmaceuticals · doi:10.3390/ph16050750 · Cited by 29
Leiter, L. A., Raal, F. J., Schwartz, G. G., Koenig, W., Ray, K. K., Landmesser, U., Han, J., Conde, L. G., & Wright, R. S. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15650 · Cited by 27
Self-citationZac‐Varghese, S., Mark, P. B., Bain, S. C., Banerjee, D., Chowdhury, T. A., Dasgupta, I., De, P., Fogarty, D. G., Frankel, A., Goldet, G., et al. (2024) · BMC Nephrology · doi:10.1186/s12882-024-03664-1 · Cited by 26
Dhara, D., Hill, A. C., Ramesh, A., Wood, M. J. A., El-Sagheer, A. H., & Brown, T. P. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c11402 · Cited by 27
The functions of apolipoproteins and lipoproteins in health and disease
Ma, Z., Zhong, J., Tu, W., Li, S., & Chen, J. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00218-7 · Cited by 36
Parhofer, K. G., Aguíar, C., Banach, M., Drexel, H., Gouni‐Berthold, I., de Isla, L. P., Rietzschel, E. R., Zambon, A., & Ray, K. K. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf007 · Cited by 31
Self-citationNanotheranostics Revolutionizing Gene Therapy: Emerging Applications in Gene Delivery Enhancement
Guzmán-Sastoque, P., Rodríguez, C. F., Monsalve, M. C., Castellanos, S., Manrique-Moreno, A., Reyes, L. H., & Cruz, J. C. (2025) · Journal of Nanotheranostics · doi:10.3390/jnt6020010 · Cited by 31
Secondary Prevention of Cardiovascular Disease in Women: Closing the Gap
Thakkar, A., Agarwala, A., & Michos, E. D. (2021) · European Cardiology Review · doi:10.15420/ecr.2021.24 · Cited by 30
RNA-based therapy in the management of lipid disorders: a review
Blom, D. J., Marais, A. D., Moodley, R., van der Merwe, N., van Tonder, A., & Raal, F. J. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01649-3 · Cited by 29
Self-citationThe Promise of PCSK9 and Lipoprotein(a) as Targets for Gene Silencing Therapies
Chan, D. C., & Watts, G. F. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.07.008 · Cited by 30
Efficacy, Safety, and Pharmacokinetics of Inclisiran in Japanese Patients: Results from ORION-15
Yamashita, S., Kiyosue, A., Maheux, P., Mena-Madrazo, J., Lesogor, A., Shao, Q., Tamaki, Y., Nakamura, H., Akahori, M., & Kajinami, K. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64454 · Cited by 26
Mansfield, B. S., Mohamed, F., Larouche, M., & Raal, F. J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13144160 · Cited by 28
Self-citationTherapeutic PCSK9 targeting: Inside versus outside the hepatocyte?
Corsini, A., Ginsberg, H. N., & Chapman, M. J. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108812 · Cited by 27
Mauriello, A., Correra, A., Maratea, A. C., Caturano, A., Liccardo, B., Perrone, M. A., Giordano, A., Nigro, G., D’Andrea, A., & Russo, V. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14051652 · Cited by 29
Novel RNAi-Based Therapies for Atherosclerosis
Ruotsalainen, A., Mäkinen, P. I., & Ylä‐Herttuala, S. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00938-z · Cited by 26
Burnett, H. F., Fahrbach, K. R., Cichewicz, A. B., Jindal, R., Tarpey, J., Durand, A., Domenico, M. D., Reichelt, A., & Viljoen, A. (2022) · Current Medical Research and Opinion · doi:10.1080/03007995.2022.2049164 · Cited by 32
Inclisiran: How Widely and When Should We Use It?
Pirillo, A., & Catapano, A. L. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01056-0 · Cited by 27
Kumrić, M., Urlić, H., Božić, J., Vilović, M., Kurir, T. T., Glavaš, D., Miric, D., Zanchi, J., Bradarić, A., Lozo, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098062 · Cited by 27
LDL-cholesterol target levels achievement in high-risk patients: An (un)expected gender bias
Berteotti, M., Profili, F., Nreu, B., Casolo, G., Zuppiroli, A., Mannucci, E., Marcucci, R., & Francesconi, P. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.09.023 · Cited by 26
Lipoprotein(a)—60 Years Later—What Do We Know?
Pasławska, A., & Tomasik, P. (2023) · Cells · doi:10.3390/cells12202472 · Cited by 31
Safety and Lipid-Lowering Efficacy of Inclisiran Monotherapy in Patients Without ASCVD
Taub, P. R., Gutierrez, A., Wewers, D., Garcia Cantu, E., Cao, H., Deck, C., Lesogor, A., Ott, D., Mena-Madrazo, J., Zang, X., et al. (2025) · JACC · doi:10.1016/j.jacc.2025.04.049 · Cited by 25
Self-citationLipid-Lowering Therapy after Acute Coronary Syndrome
Pogran, E., Burger, A. L., Zweiker, D., Kaufmann, C. C., Muthspiel, M., Rega‐Kaun, G., Wenkstetten-Holub, A., Wojta, J., Drexel, H., & Huber, K. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13072043 · Cited by 27
Broader Perspective on Atherosclerosis—Selected Risk Factors, Biomarkers, and Therapeutic Approach
Fularski, P., Czarnik, W., Dąbek, B., Lisińska, W., Radzioch, E., Witkowska, A., Młynarska, E., Rysz, J., & Franczyk, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105212 · Cited by 26
Burgess, S. N., Zaman, S. J., Towns, C. R., Coylewright, M. J., & Cader, F. A. (2024) · American Heart Journal · doi:10.1016/j.ahj.2024.12.011 · Cited by 34
Mathur, S., Chaturvedi, A., & Ranjan, R. (2025) · Nanoscale Advances · doi:10.1039/d5na00044k · Cited by 27
Nanotechnology-Enhanced siRNA Delivery: Revolutionizing Cancer Therapy
Esmaeilpour, D., Ghomi, M., Zare, E. N., & Sillanpää, M. E. T. (2025) · ACS Applied Bio Materials · doi:10.1021/acsabm.5c00489 · Cited by 31
Inclisiran: a new milestone on the PCSK9 road to tackle cardiovascular risk
Santulli, G., Jankauskas, S. S., & Gambardella, J. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab014 · Cited by 27
Managing dyslipidemia in patients with Type 2 diabetes
Tomlinson, B., Patil, N. G., Fok, M., & Lam, C. W. K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1912734 · Cited by 25
MiR-337-3p lowers serum LDL-C level through targeting PCSK9 in hyperlipidemic mice
Xu, X., Dong, Y., Ma, N., Kong, W., Yu, C., Gong, L., Chen, J., & Ren, J. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154768 · Cited by 24
Lipid-lowering therapy and percutaneous coronary interventions
Koskinas, K. C., Mach, F., & Räber, L. (2021) · EuroIntervention · doi:10.4244/eij-d-20-00999 · Cited by 26
Cold shock domain-containing protein E1 is a posttranscriptional regulator of the LDL receptor
Smith, G. A., Padmanabhan, A., Lau, B. H., Pampana, A., Li, L., Lee, C. Y., Pelonero, A., Nishino, T., Sadagopan, N., Xia, V. Q., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abj8670 · Cited by 23
Management of patients with statin intolerance
Martirossian, A. N., & Goldberg, A. C. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101714 · Cited by 27
The formation and consequences of cholesterol-rich deposits in atherosclerotic lesions
Maxfield, F. R., Steinfeld, N., & Ma, C.-I. J. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1148304 · Cited by 27
Gogate, A., Belcourt, J., Shah, M., Wang, A., Frankel, A., Kolmel, H., Chalon, M., Stephen, P., Kolli, A., Tawfik, S. M., et al. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.123.000815 · Cited by 27
Dyslipidemia: A Narrative Review on Pharmacotherapy
de Oliveira, L. D., de Assis, A. C. R., Giraldez, V. Z. R., Scudeler, T. L., & Soares, P. R. (2024) · Pharmaceuticals · doi:10.3390/ph17030289 · Cited by 26
Clinical Implications and Outcomes of the Orion Phase Iii Trials
Brandts, J., & Ray, K. K. (2020) · Future Cardiology · doi:10.2217/fca-2020-0150 · Cited by 30
Self-citationThe year in cardiovascular medicine 2020: epidemiology and prevention
Estruch, R., Ruilope, L. M., & Cosentino, F. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa1062 · Cited by 26
The effect of PCSK9 inhibitors on brain stroke prevention: A systematic review and meta-analysis
Qin, J., Liu, L., Su, X. D., Wang, B. B., Fu, B. S., Cui, J., & Liu, X. Y. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.03.026 · Cited by 26
Emerging Anti-Atherosclerotic Therapies
Gluba-Brzózka, A., Franczyk, B., Rysz-Górzyńska, M., Ławiński, J., & Rysz, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212109 · Cited by 28
Therapeutic advances in alcohol-associated hepatitis
Szabó, G., Thursz, M. R., & Shah, V. H. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.03.025 · Cited by 24
SAMSON and the Nocebo Effect: Management of Statin Intolerance
Krishnamurthy, A., Bradley, C., Ascunce, R. R., & Kim, S. M. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01729-x · Cited by 25
Asbeutah, A. A., Asbeutah, S. A., & Abu-Assi, M. A. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.05.024 · Cited by 24
Nucleic acids therapeutics using PolyPurine Reverse Hoogsteen hairpins
Noé, V., Aubets, E., Félix, A. J., & Ciudad, C. J. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114371 · Cited by 24
The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?
Miname, M. H., Rocha, V. Z., & Santos, R. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00936-1 · Cited by 25
Rare Genetic Variants in LDLR , APOB , and PCSK9 Are Associated With Aortic Stenosis
Rämö, J. T., Jurgens, S. J., Kany, S., Choi, S. H., Wang, X., Smirnov, A. N., Friedman, S. F., Maddah, M., Khurshid, S., Ellinor, P. T., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.070982 · Cited by 26
Metadata
- Authors
- Ray, K. K., Wright, R. S., Kallend, D., Koenig, W., Leiter, L. A., Raal, F. J., Bisch, J. A., Richardson, T., Jaros, M., Wijngaard, P. L. J., & Kastelein, J. J. P.
- Affiliations
- Mayo Clinic (US)
- From the Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London (K.K.R.); the Department of Cardiology, Mayo Clinic, Rochester, MN (R.S.W.); the Medicines Company, Zurich, Switzerland (D.K.); Deutsches Herzzentrum München, Technische Universität München, and Deutsches Zentrum für Herz-Kreislauf-Forschung (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, and the Institute of...
- St. Michael's Hospital (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-04-16
- Volume
- 382
- Issue
- 16
- Pages
- 1507-1519
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3012265841
- Semantic Scholar
- 0c86cfdc39f60ff6dc8854a281c1b95f32bdc692
- Cited by
- 1,665
- References
- 19
- Citations by year
- 2026: 296 · 2025: 290 · 2024: 289 · 2023: 273 · 2022: 231 · 2021: 193 · 2020: 87
- FWCI
- 183.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- The Medicines Company
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- inclisiran, PCSK9 inhibition, LDL cholesterol lowering, atherosclerotic cardiovascular disease, statin therapy, injection-site adverse events, hypercholesterolemia, lipid-lowering therapy, adverse events, drug safety and efficacy
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Aged, Aged, 80 and over, Anticholesteremic Agents, Cardiovascular Diseases, Coronary Artery Disease, Double-Blind Method, Drug Administration Schedule, Female, Humans, Hypercholesterolemia, Injections, Subcutaneous, Cholesterol, LDL, Liver Function Tests, Male, Middle Aged, Risk Factors, Hydroxymethylglutaryl-CoA Reductase Inhibitors, RNA, Small Interfering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
